Core Viewpoint - Ironwood Pharmaceuticals, Inc. has announced its financial guidance for the full year 2026, highlighting significant progress in maximizing LINZESS and maintaining sustained profits and cash flows to strengthen its financial position and comply with debt covenants [1] Financial Performance - In 2025, the company made substantial advancements in its operations, particularly with LINZESS, which contributed to sustained profits and cash flows [1] - The focus on financial stability is aimed at ensuring compliance with debt covenants in the upcoming periods [1]

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference. ...

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].

Core Insights - AbbVie Inc. is a global pharmaceutical company with a market cap of $403.8 billion, focusing on various health issues across multiple therapeutic areas [1] Financial Performance - Analysts expect AbbVie to report a profit of $3.37 per share for Q4 2025, a 56% increase from $2.16 per share in the same quarter last year [2] - For the full year, AbbVie is projected to report an EPS of $10.65, reflecting a 5.2% increase from $10.12 in fiscal 2024, with an anticipated rise to $14.42 in fiscal 2026, representing a 35.4% year-over-year growth [3] Stock Performance - AbbVie stock has outperformed the S&P 500 Index, gaining 29.7% over the past 52 weeks compared to the index's 16.4% increase [4] - The stock also surpassed the Health Care Select Sector SPDR Fund's 12.8% returns during the same period [4] Growth Drivers - The company's strong performance is attributed to the success of its drugs Skyrizi and Rinvoq, double-digit growth in neuroscience, and strategic acquisitions such as Gilgamesh and Capstan Therapeutics [5] - AbbVie is expanding its manufacturing capabilities with a $195 million investment in North Chicago and a $70 million expansion in Worcester, while advancing pipeline programs for alopecia areata, vitiligo, and Parkinson's disease [5] Recent Earnings Report - On October 31, AbbVie reported a Q3 adjusted EPS of $1.86, exceeding Wall Street's expectations of $1.77, with revenue of $15.8 billion, also surpassing the forecast of $15.6 billion [6] - The company expects its full-year adjusted EPS to be in the range of $10.61 to $10.65 [6] Analyst Ratings - The consensus opinion on AbbVie stock is moderately bullish, with a "Moderate Buy" rating from 28 analysts; 16 recommend a "Strong Buy," 1 a "Moderate Buy," and 11 a "Hold" [7] - AbbVie's average analyst price target is $245.81, indicating a potential upside of 7.6% from current levels [7]

美国流感季疫情加剧，新毒株出现或导致疫苗防护效果下降，新冠病例则持续处于低位。 ▸ 核心提要 美国流感确诊病例连日走高，疾控部门担忧当前流感疫苗对流行的新毒株防护效果不足。公共卫生专家 表示，本轮流感季虽已进入高发期，但尚未达峰值，病例激增符合往年流感季的流行规律，疫苗仍能有 效降低重症风险。新冠疫情则持续缓和，污水监测数据显示病毒传播水平远低于夏季峰值。 文 / 戴维・奥瓦列 美国流感确诊病例呈上升趋势，主导疫情的是一种新型流感毒株，公共卫生部门担忧现有疫苗无法对其 形成有效防护。 卫生官员与研究人员指出，尽管本轮流感季尚未迎来峰值，此次病例激增并非历史罕见情况，同时强调 疫苗大概率仍能抵御该毒株引发的重症风险。 美国疾控中心数据显示，流感相关的住院、急诊、门诊就诊人次及死亡病例均大幅上升，不过美国流感 疫情峰值预计要到明年初才会到来，大概率在 2 月。 布朗大学公共卫生学院大流行病研究中心主任、流行病学家詹妮弗・努佐表示："本轮流感病例增长虽 略显迅猛，但实属正常。流感季的疫情传播向来来势汹汹。" 冬季的环境条件极易助长流感、新冠、呼吸道合胞病毒等空气传播类病毒的扩散，民众长期聚集在室 内、节假日出行增多 ...

We recently published 10 Market Stars Behind Millionaire-Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers. Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its therapy candidate for chronic myeloid leukemia (CML), which has the potential to become the best-in-class therapy versus other existing treatments. At the 67th American Society of Hematology (ASH) Annual Meeting and Exposition early last mon ...

We recently published 10 Market Stars Behind Millionaire-Making in 2025. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the top performers. Cidara Therapeutics climbed by 721.76 percent in 2025, primarily bolstered by its looming merger with Merck for $9.2 billion. In an announcement last November, Cidara Therapeutics Inc. (NASDAQ:CDTX) said that it signed a definitive agreement with Merck, under which the latter’s subsidiary would acquire the former’s issued and outstanding shares at a price of $221.50 ...

We recently published 10 Market Stars Behind Millionaire-Making in 2025. ABIVAX Societe Anonyme (NASDAQ:ABVX) is last year's top performer. Abivax skyrocketed by 1,742.28 percent in 2025, as investor sentiment was primarily bolstered by a series of upbeat analyst outlooks, strong clinical trial results, and its official inclusion in Nasdaq’s biotechnology index. ABIVAX Societe Anonyme (NASDAQ:ABVX) officially joined the Nasdaq biotechnology index (NBI) on December 22, designed to track the performance of a ...

Group 1 - The traditional Chinese medicine industry in Jiangkou County, Guizhou is experiencing a peak in production and sales [1] - Jiangkou Gurun Pharmaceutical is collaborating with China National Pharmaceutical Group to implement order-based production, aiming for a sales value of 12 million yuan for dry Epimedium products by 2025 [3] - Guizhou Miao Medicine Biotechnology Co., Ltd. focuses on the extraction of Miao medicine and health product development, with a projected total sales exceeding 17 million yuan by 2025, representing a 50% year-on-year growth [5] Group 2 - Jiangkou County has a high forest coverage rate and suitable climate, making it rich in traditional Chinese medicine resources, with a planting area of 51,500 acres for key varieties like Epimedium and Huangjing [7] - The county is promoting the standardization and branding of the traditional Chinese medicine industry, aiming to make "small medicinal materials" a significant asset for local economic development [8]

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a current reading of 45.8, down from 48.4 [1][4] - U.S. stocks settled lower, with the Dow Jones index falling more than 300 points, closing at 48,063.29, while the S&P 500 and Nasdaq Composite also recorded declines [1][3] Stock Performance - The S&P 500 increased by 16.39% for the year, marking its third consecutive double-digit annual surge, while the Nasdaq Composite gained 20.36% and the Dow added 12.97% in 2025 [2] - Vanda Pharmaceuticals Inc. saw its shares jump over 25% after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [2] - FuelCell Energy Inc. experienced an 8% decline in its shares following the filing for an amended common stock offering [2] Economic Data - U.S. initial jobless claims decreased by 16,000 to 199,000 for the week ending December 27, which was better than market estimates of 220,000 [3] - All sectors on the S&P 500 closed negatively, with real estate, industrials, and materials stocks experiencing the largest losses [3]